Efficacy, safety, and tolerability of brivaracetam with concomitant lamotrigine or concomitant topiramate in pooled Phase III randomized, double-blind trials: A post-hoc analysis

•This is a post-hoc analysis to assess the efficacy and safety of BRV administered with concomitant LTG or TPM•≥50%, ≥75%, ≥90%, & 100% responder rates in patients on BRV ≥50 mg/day with concomitant LTG or TPM were higher than placebo•No conclusions can be drawn regarding the efficacy of BRV when combined with either LTG or TPM due to low patient numbers•Results support the safety and tolerability of BRV when taken with concomitant LTG or TPM